Cancer therapy developer G1 Therapeutics has gone public in an initial public offering that gave an exit to long-time investor MedImmune Ventures.
MedImmune, a biotech subsidiary of pharmaceutical firm AstraZeneca, exited US-based cancer therapeutics developer G1 Therapeutics yesterday in a $105m initial public offering on Nasdaq.
G1 issued 7 million shares priced at $15.00 each, at the foot of its $15 to $17 range, giving it a market value of approximately $410m.
Founded in 2012 and based on research from North Carolina University’s Lineberger Comprehensive Cancer Center, G1 is developing cancer treatments that focus on a family of proteins called cyclin-dependent…
